{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-114763","form_type":"8-K","ticker":"KTTA","cik":"0001841330","company_name":"Pasithea Therapeutics Corp.","filed_at":"2025-11-25T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.756411+00:00","generated_at":"2026-05-16T17:02:40.163792+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Pasithea reports Phase 1 partial response for PAS-004 in advanced cancer; ALS Association awards $1M grant","bullets":["BRAF V600E melanoma patient achieved -31.9% tumor reduction on PAS-004 monotherapy; remains on trial >11 months.","Overall disease control rate 71.4% in BRAF-mutated tumors; no DLTs or discontinuations across 27 patients.","PAS-004 tablet formulation shows 3-fold higher dose-normalized exposure vs capsule with less variability.","Cohort 7 (37mg capsule): zero TRAEs in DLT period; 80% pERK inhibition at Cmax; SRC clears escalation to 45mg.","ALS Association awards ~$1M grant for Phase 1 study of PAS-004 in 12 ALS patients (safety, ALSFRS-R, NfL)."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-114763","json":"https://secwatch.observer/filing/0001213900-25-114763.json","markdown":"https://secwatch.observer/filing/0001213900-25-114763.md","text":"https://secwatch.observer/filing/0001213900-25-114763.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1841330/000121390025114763/0001213900-25-114763-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1841330/000121390025114763/ea0266606-8k_pasithea.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T17:02:40.163792+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}